21 research outputs found
Monitoring and Control of a Continuous Grignard Reaction for the Synthesis of an Active Pharmaceutical Ingredient Intermediate Using Inline NIR spectroscopy
Continuous Hydrolysis and Liquid–Liquid Phase Separation of an Active Pharmaceutical Ingredient Intermediate Using a Miniscale Hydrophobic Membrane Separator
Development of a Multi-Step Synthesis and Workup Sequence for an Integrated, Continuous Manufacturing Process of a Pharmaceutical
Specificity of receptor-G protein interactions. Discrimination of Gi subtypes by the D2 dopamine receptor in a reconstituted system.
Two forms of the bovine brain Go that stimulate the inositol trisphosphate-mediated Cl- currents in Xenopus oocytes. Distinct guanine nucleotide binding properties
Continuous Hydrolysis and Liquid–Liquid Phase Separation of an Active Pharmaceutical Ingredient Intermediate Using a Miniscale Hydrophobic Membrane Separator
Continuous hydrolysis of an active pharmaceutical ingredient
intermediate, and subsequent liquid–liquid (L-L) separation
of the resulting organic and aqueous phases, have been achieved using
a simple PTFE tube reactor connected to a miniscale hydrophobic membrane
separator. An alkoxide product, obtained in continuous mode by a Grignard
reaction in THF, reacted with acidic water to produce partially miscible
organic and aqueous phases containing Mg salts. Despite the partial
THF–water miscibility, the two phases could be separated at
total flow rates up to 40 mL/min at different flow ratios, using a
PTFE membrane with 28 cm2 of active area. A less challenging
separation of water and toluene was achieved at total flow rates as
high as 80 mL/min, with potential to achieve even higher flow rates.
The operability and flexibility of the membrane separator and a plate
coalescer were compared experimentally as well as from a physical
viewpoint. Surface tension-driven L-L separation was analyzed in general
terms, critically evaluating different designs. It was shown that
microporous membrane L-L separation can offer very large operating
windows compared to other separation devices thanks to a high capillary
pressure (Laplace pressure) combined with a large number of pores
per unit area offering low pressure drop. The separation device can
easily be operated by means of a back-pressure regulator ensuring
flow-independent separation efficiency. Simple monitoring and control
strategies as well as scaling-up/out approaches are proposed, concluding
that membrane-based L-L separation may become a standard unit operation
for continuous pharmaceutical manufacturing
Implementation of Near-Infrared Spectroscopy for In-Line Monitoring of a Dehydration Reaction in a Tubular Laminar Reactor
Production of active pharmaceutical
ingredients (APIs), fine chemicals,
food products, and so on has in recent years been focused on implementing
process intensification and process optimization tools. Lower costs
and higher selectivity as well as better sustainability and competitiveness
are the main benefits. A good approach to achieve this is to perform
continuous manufacturing together with satisfying process analytical
technology (PAT) requirements. The example studied here is the dehydration
reaction of 9-allyl-2-chlorothioxanthen-9-ol (“N714-allylcarbinol”)
to give a mixture of <i>cis</i>- and <i>trans</i>-9<i>H</i>-thioxanthene, 2-chloro-9-(2-propenylidene)-(9CI)
(“N746-butadienes”). A simplified procedure for designing
mesoscale tubular reactors is demonstrated together with performance
outside of the normal operation windows (higher pressures and temperatures
above normal boiling points of solvents). Noninvasive in-line real-time
monitoring was established by using Fourier transform near-infrared
(FT-NIR) spectroscopy and a suitable partial least squares (PLS) model.
High prediction accuracy was achieved and additionally validated by
using at-line FT-NIR spectroscopy and off-line HPLC analysis. The
presence of impurities was noticed and partly identified in the form
of polymers. It is important to note that substrates and products
in this work are API intermediates in the production of zuclopenthixol,
a product of H. Lundbeck A/S
